UPDATE 1-Germany's Merck says EU approves new Rebif version
(Adds detail, share price)
FRANKFURT Aug 30 (Reuters) - German drug maker Merck KGaA's (MRCG.DE) Merck Serono unit won European Commission approval to market a new formulation of its Rebif drug to treat relapsing multiple sclerosis, the company said on Thursday.
The new Rebif has been designed to be better tolerated when injected, Merck said in a statement.
The marketing authorisation covers all 27 European Union countries, as well as Norway, Iceland and Liechtenstein, Merck said, adding that the drug would be launched in various EU countries starting next month.
"This new formulation will represent an improvement in the therapy of MS patients being treated with Rebif," said Per Soelberg Soerensen, of the Danish Multiple Sclerosis Research Centre at Copenhagen University Hospital, in the statement.
Shares in Merck were 0.3 percent higher at 90.88 euros by 0731 GMT, compared with a 0.5 percent gain on the German blue-chip DAX index .GDAXI. The DJ healthcare index .SXDP was 0.1 percent higher.
((Reporting by Peter Starck and James Regan, editing by Will Waterman; frankfurt.newsroom@news.reuters.com; Reuters Messaging: peter.starck.reuters.com@reuters.net; +49 69 7565 1217)) Keywords: MERCK REBIF/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL3059326
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters